Business

Dr. Scott Gottlieb reviews Pfizer’s Covid booster approval process

Dr. Scott Gottlieb, a former Food and Drug Administration commissioner, told CNBC that he expects the Centers for Disease Control and Prevention to soon identify who is eligible for Covid booster doses.

Gottlieb, Pfizer Board members detailed the FDA and CDC booster approval process in an interview on Tuesday.News with Shepard Smith.. “FDA You can make a formal decision Regarding Pfizer’s booster, Gottlieb said health officials could extend the FDA’s instructions before the CDC began a two-day series of meetings with a third dose on Wednesday and Thursday.

“They provide detailed guidance to doctors and patients and interpret the recommendations made by the Food and Drug Administration,” Gottlieb said of the CDC. “For example, they might say that they might list strict conditions that would qualify someone as a booster.”

FDA Advisory Board Refused the plan on Friday It would have allowed all Americans 16 years and older to receive a third dose and expressed reservations for inadequate data and risk of myocarditis. However, the Commission then unanimously voted to approve boosters for those who are medically vulnerable and those over the age of 65.

Gottlieb said the process sent conflicting messages about who would be the target of boosters, but whenever the FDA cast two votes to narrow down the potential recipients of Pfizer’s third dose. He added that he was thinking.

“I think the meeting has created a perception that there may be conflicting messages, I don’t think so,” Gottlieb said. “The FDA initially voted for boosters for all ages 16 and older, but eventually made boosters available to people over 65 and those at risk of serious consequences from Covid. I have agreed to a recommendation to do so. I am at greater risk from the disease itself. It always seemed like the FDA was heading administratively. “

Former Commissioner of Food and Drugs, Dr. Scott Gottlieb, spoke at SkyBridge Capital SALT New York 2021 on September 15, 2021 in New York City, USA.

Brendan MacDermid | Reuters

Gottlieb added, “I think it created the perception that government agencies voted against boosters before they voted for boosters. It wasn’t. I think it was a more administrative action and it caused public turmoil. “He added.

Vaccine maker while Pfizer is waiting for booster final approval Modana When Johnson & Johnson Both have released data they say justify the approval of their own supplemental doses. J & J said Tuesday that Covid Booster was 94% effective when injected two months after the first dose. Meanwhile, Moderna reported a breakthrough case reduction in recently vaccinated participants in a study published on September 15.

According to the CDC, more than 2.2 million people have received boosters in the United States since August 13.

Disclosure: Scott Gottlieb is a CNBC contributor and member of the board of directors of Pfizer, genetic testing startup Tempas, healthcare technology company Etion, and biotechnology company Illumina. He is also Co-Chair of Norwegian Cruise Line Holdings and Royal Caribbean’s “Healthy Sail Panel”.

Dr. Scott Gottlieb reviews Pfizer’s Covid booster approval process

Source link Dr. Scott Gottlieb reviews Pfizer’s Covid booster approval process

Back to top button